Skip to main content

Antithrombotic Strategies in Patients Undergoing Elective Percutaneous Coronary Intervention

Publication ,  Journal Article
Rao, SV; Ohman, EM
October 3, 2012

The goals of antithrombotic therapy during percutaneous coronary intervention are to mitigate thrombotic complications associated with iatrogenic plaque disruption from the angioplasty balloon or stent and embolization of thrombotic material from procedural equipment. Available therapies are directed against thrombin and platelets and evidence-based regimens include combinations of unfractionated heparin, low molecular weight heparin, bivalirudin, aspirin, glycoprotein IIb/IIIa inhibitors, and clopidogrel. Data supporting each strategy are presented as are dosing recommendations. © 2013 Blackwell Publishing Ltd.

Duke Scholars

DOI

Publication Date

October 3, 2012

Start / End Page

236 / 245
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Rao, S. V., & Ohman, E. M. (2012). Antithrombotic Strategies in Patients Undergoing Elective Percutaneous Coronary Intervention, 236–245. https://doi.org/10.1002/9781118410875.ch16
Rao, S. V., and E. M. Ohman. “Antithrombotic Strategies in Patients Undergoing Elective Percutaneous Coronary Intervention,” October 3, 2012, 236–45. https://doi.org/10.1002/9781118410875.ch16.
Rao, S. V., and E. M. Ohman. Antithrombotic Strategies in Patients Undergoing Elective Percutaneous Coronary Intervention. Oct. 2012, pp. 236–45. Scopus, doi:10.1002/9781118410875.ch16.

DOI

Publication Date

October 3, 2012

Start / End Page

236 / 245